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Abstract
Background: The aim of this study was to compare treatment of moderate to severe symptomatic mitral
regurgitation (MR) with either conventional surgery or the mitral valve edge-to-edge device (MitraClip®) in very elderly
patients. The newly introduced MitraClip device has demonstrated promising acute results in treating this patient
cohort. Also noteworthy is the fact that patients who otherwise would have been denied surgery are increasingly
referred for treatment with the MitraClip device. We sought to review our institutional experience, comparing
outcomes in both surgical and MitraClip arms of treatment in the elderly population with symptomatic MR.
Methods: From October 2008 through October 2014, 136 consecutive patients aged≥ 80 with moderate to severe
symptomatic MR were scheduled for either conventional surgery or MitraClip intervention. 56 patients≥ 80 were
operated for symptomatic MR and 80 patients≥ 80 were treated with the mitraClip device. Patients suitable for this
study were identified from our hospital database. Patients ≥80 with moderate/severe symptomatic MR treated with
either conventional surgery or the MitraClip device were eligible for our analysis. We compared the surgical patient
cohort with the mitraClip patient cohort after eliminating patients that did not meet our inclusion criteria. Forty-two
patients were identified from the conventional cohort who were then compared with 42 patients from the mitraClip
cohort. Forty-two patients (50%) underwent mitral valve repair or replacement (40.5% functional MR, 59.5% organic/
mixed MR) and 42 patients (50%) underwent MitraClip intervention (50% functional MR, 50% organic/mixed MR).
Associated procedures in the conventional surgical group were myocardial revascularization 38%, pulmonary vein
ablation 23.8%, left atrial appendage resection 52.4% and PFO occlusion 11.9%.
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Results: Patients who underwent MitraClip treatment were though slightly older but the differences did not attain
statistical significance (mean, 82.2 ± 1.65 vs 81.7 ± 1.35 years, p = 0,100), had lower LVEF (mean, 47.6 ± 14.2 vs 53.4 ± 14.
3, p = 0.072), lower logistic EuroScore II (mean, 11.3 ± 5.63 vs 12.1 ± 10.6, p = 0.655) but higher STS risk score (mean, 11.
8 ± 6.7 vs 8.1 ± 5.6, p = 0.008) respectively compared to surgical patients. Procedural success was 100% vs 96% in
surgery and MitraClip groups respectively. Thirty -day mortality was 7.1% vs 4.8% (p = 1.000) in surgery and MitraClip
group respectively. Residual postoperative MR ≥2 at discharge was present in none of the patients treated surgically,
whereas this was the case in 10 (23.8%) patients treated with the MitraClip device. At 1 year a cumulative number of
four (9.52%) patients died in the surgical group vs 9 (21.4%) patients who died in the MitraClip group.
Conclusions: Elderly patients presenting with moderate to severe symptomatic MR may either be treated by
conventional surgery or with the MitraClip device with acceptable acute outcomes. The decision for treatment with
the MitraClip device should not depend on age alone rather on cumulative risk of conventional surgery. Concomitant
cardiac pathologies, often times treated simultaneously during surgery for symptomatic MR may be omitted, if patients
are scheduled outright to MitraClip treatment. The effect of concomitant cardiac pathologies left untreated at the time
of interventional mitral valve repair on outcome after MitraClip therapy remain widely unknown.
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Background
More than 9% of patients ≥75 years have significant MR
[1]. The proportion of individuals aged ≥75 with symp-
tomatic MR is estimated to become a growing clinical
problem. The decision whether to refer an elderly pa-
tient with symptomatic MR for mitral valve surgery and
appropriate timing of referral is a highly debated issue.
Age, severe MR and reduced left ventricular function
amongst others have been identified as independent pa-
tient factors associated with non referal for mitral valve
surgery [2]. Though, due to outstanding improvements
in diagnostic modalities, patient selection criteria and
operative techniques over the years, the operative mor-
tality, in-hospital morbidity and long term outcomes as-
sociated with mitral valve surgery has significantly
improved [3]. However, the benefit of surgery in the very
elder population despite these significant improvements
over the years has not been clearly documented. Increas-
ing life expectancy and associated increase in the preva-
lence of valvular heart diseases, especially MR amongst
the very elderly population is expected to become a ris-
ing clinical problem in the industrialized nations. Many
patients at this advanced age will likely present with
concomitant cardiac pathologies, necessitating surgical
attention [4, 5]. The novel MitraClip device is antici-
pated to play a crucial role in addressing MR in this eld-
erly patient population. In this context, staged
percutaneous management of concomitant pathologies
may be feasible in some cases. Coronary heart disease,
aortic valve stenosis and certain pathologic rhythms may
be treated in a staged total percutaneous manner. Data
on the fate of moderate tricuspid regurgitation left un-
treated during conventional surgery remain insufficient
and this is equally the case with percutaneous mitral
valve repair. The impact of these residual pathologies on
short and long term outcome has not been fully evalu-
ated, leaving complete surgical intervention as gold
standard [6]. Though there are indications that the novel
MitraClip device may confer superior acute outcomes,
with lower procedural mortality in symptomatic patients,
however, long term outcomes, especially in the very eld-
erly is not well known. The impact of residual MR, atrial
septal defect, atrial fibrillation, incomplete revasculariza-
tion and tricuspid valve disease in this patient popula-
tion treated with the MitraClip device is not known.
Despite higher mortality and morbidity in the acute
phase post surgery, surgery in most cases offer complete
repair of concomitant cardiac pathologies [7–10]. We
sought to compare the overall outcome of conventional
mitral valve surgery vs MitraClip treatment in a single
center cohort of 84 patients.
Patient selection and methods
Patient selection
The criteria for selecting patients eligible for MitraClip
intervention has been previously described by Para-
nskaya et al. [11]. We at first found 80 patients who
underwent mitraClip intervention. Forty-two patients
were found suitable for comparing with the surgical
cohort. In the surgical arm, we retrospectively selected
patients ≥80 years who presented with moderate/severe
symptomatic MR and were treated with conventional
surgery with the aim of comparing them with a similar
MitraClip treatment population.
A team of experienced cardiac surgeons, cardiologists
and anesthesiologists selected patients eligible for conven-
tional surgery and decision was based on the guidelines as
stipulated by the joint task force on the management of
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valvular heart diseases of the European Society of Cardi-
ology [12]. Transthoracic echocardiography (TTE) followed
by transoesophageal echocardiography (TEE) examination
at baseline were applied for general screening purposes. A
search into our department surgical database for patients ≥
80 who received mitral valve surgery (repair or replace-
ment) during this time frame yielded at first 56 patients.
Forty-two patients suitable for our analysis were retained
after excluding patients with concomitant tricuspid-, aortic
valve surgeries, mitral valve stenosis, active endocarditis of
any valve or intracardiac structures and emergency settings
requiring hemodynamic or respiratory support prior to sur-
gery (Table 1 depicts concomitant procedures in the surgi-
cal group). In-hospital data were retrospectively retrieved
from each patient’s personal file. Surgical patients who
received concomitant myocardial revascularization were
included because MitraClip patients with significant coron-
ary stenosis received percutaneous coronary interventions
prior to MitraClip therapy. All patients with justifiable
EuroScore II and STS scores were referred for surgery after
obtaining informed consent.
Methods
This study is based on our experience with very elderly
patients with symptomatic moderate- severe MR, who
underwent correction of this valve pathology during the
period between October 2008 and October 2014.
Patients underwent surgical correction of MR with ei-
ther mitral valve repair, replacement or placement of ≥1
MitraClip devices. A retrospective assessment was then
perfomed after all follow-up data were retrieved. This
was accomplished by obtaining all medical records from
nursing home personnel, family physician or patient/
family members. Follow- up was obtained at different in-
tervals post index procedure (last survey or death) in all
84 patients included in this study.
Follow-up
All patients were followed up after discharge by the fam-
ily physicians and cardiologist with regular physical
examination, including evaluation of NYHA score, ECG,
TTE and TEE if need be. This was at first performed
during the first 3 months post treatment and then
dependent on clinical status at 6 months and on yearly
basis there after. Two surgical patients were lost to
follow-up. All other patients discharged alive from hos-
pital were followed up at different intervals post index
procedure.
Treatment procedures
Mitral valve surgery was performed via median sternot-
omy in all 42 surgical patients. Cardio pulmonal bypass
was installed and valve repair or replacement with vari-
able concomitant surgical procedures on the arrested
heart under mild hypothermia (32 °C) performed. Access
to mitral valve was gained either via a direct left atrial or
trans septal incision depending on weather PFO occlu-
sion was planned. Complete rigid or semi rigid annulo-
plasty rings or in case of valve replacement solely tissue
prosthesis used. All procedures were quality controlled
using intra operative TEE. MitraClip treatment was per-
formed in the hybrid suit as previously described by
paranskaya et al. [11].
Statistical analysis
Statistical analysis was conducted by using SPSS statis-
tical package 22.0 (SPSS Inc. Chicago, Illinois, USA).
Descriptive statistics were computed for continuous and
categorical variables. The statistics computed included
mean and standard deviations (SD) of continuous






Age (years), mean ± SD, (n) 81.7 ± 1.35, (42) 82.2 ± 1.65, (42) 0.100῀
Female gender, n (%) 23 (54.8) 18 (42.9) 0.383*
BMI (kg/m2), mean ± SD, (n) 26.3 ± 4.30, (42) 25.9 ± 3.96, (42) 0.682῀
Previous cardiac surgery, n (%) 7 (16.7) 7 (16.7) 1.000*
Coronary artery disease, n (%) 31 (73.8) 26 (61.9) 0.350*
COPD, n (%) 10 (23.8) 14 (33.3) 0.469*
Atrial fibrillation, n (%) 23 (54.8) 29 (69.0) 0.261*
Pulmonary hypertension,
n (%)
32 (76.2) 40 (95.2) 0.026*
Chronic renal disease, n (%) 26 (61.9) 32 (76.2) 0.238*
Arterial hypertension, n (%) 36 (85.7) 39 (92.9) 0.483*
Diabetes mellitus, n (%) 14 (33.3) 18 (42.9) 0.501*
Cardiac decompensation,
n (%)
25 (59.5) 37 (88.1) 0.006*
Logistic Euroscore II, mean
± SD, (n)
12.1 ± 10.6, (42) 11.3 ± 5.63, (42) 0.655῀
NYHA functional class, n (%)
II 8 (19.0) 1 (2.4) 0.039**
III 27 (64.3) 30 (67.9)
IV 7 (16.7) 11 (21.4)
Operative Data
Previous PCI, n (%) - 7 (16.7)
Concomitant CABG, n (%) 16 (38) - -
Concomitant pulmonary
vein ablation, n (%)
10 (23.8) - -
Concomitant LAA
resection, n (%)
22 (52.4) - -
Concomitant PFO
occlusion, n (%)
5 (11.9) - -
῀ Student’s unpaired t-test
* Fisher’s exact Test for categorical data
** Chi-square test for categorical data
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variables and are presented as mean ± SD, frequencies
and relative frequencies of categorical factors. Testing
for differences of continuous variables between the study
groups was accomplished by the t-test for independent
samples or the Mann-Whitney U test, as appropriate.
Test selection was based on evaluating the variables for
normal distribution employing the Kolmogorov-Smirnov
test. Comparisons between the study groups for categor-
ical variables were done using the chi-square test or the
Fisher’s exact test. For unbiased results the matched
pairs method for the arrangement of statistical twins was
used. For the matching process a correspondence of the
parameters age, sex and MR Type was used. In specific,
matching for age was performed using frequency match-
ing to assure that cases and controls have similar distri-
butions over strata defined by age. The matching on age
involved the construction of three separate categories.
The age categories were as follows: 80–82, 83–84 and ≥
85 years respectively.
The period of time to death or last follow-up was esti-
mated using the Kaplan-Meier method. Differences be-
tween curves were assessed by Mantel’s log-rank test for
censored survival data.
The Cox proportional hazards model was used to assess
the independence of survival from prognostic factors. Uni-
variate analyses were performed by computation of hazard
ratios, 95% - confidence intervals and examination the sig-
nificance by the Wald statistic to reveal unadjusted signifi-
cant associations between prognostic variables and
survival. Altogether, p-values ≤ 0.05 were considered to be
statistically significant and all reported p-values resulted
from two-sided statistical test.
Results
Patient baseline characteristics and risk profile
From October 2008 through October 2014, 84 consecu-
tive patients aged ≥ 80 with moderate to severe symp-
tomatic MR were scheduled for either conventional
mitral valve surgery or MitraClip intervention. Patient
data were analysed retrospectively. All patients suitable
for our analysis were identified from our hospital data-
base. Patients ≥ 80 with symptomatic MR treated with
either conventional surgical or MitraClip intervention
were eligible for our analysis. Patients with concomitant
tricuspid-, aortic valve surgeries, mitral valve stenosis,
active endocarditis of any valve or intracardiac structures
and emergency settings requiring hemodynamic or
respiratory support prior to surgery were excluded from
this analysis. Patient baseline characteristics and risk
factors are depicted in Table 1.
Forty-two patients (50%) underwent mitral valve
surgery with mitral valve repair in 30 patients (71.4%) or
replacement in 12 patients (28.6%). Of the 30 patients
who received mitral valve repair, minimally invasive
(MIC) mitral valve repair was performed in five (16.7%).
Procedural success was similar (100%) in both repair
and replacement groups respectively. There was no sig-
nificant differences in both groups in terms of 30 day
mortality (2 vs 1 patients). 40.5% of surgically treated pa-
tients had functional MR whereas 59.5% had organic/
mixed MR. Forty-two patients (50%) underwent Mitra-
Clip implantation, 50% of which had functional MR
whereas 50% had organic/mixed MR respectively. Seven
patients (16.7%) in each group had previous cardiac
surgery in the past. Associated procedures in the con-
ventional surgical group were myocardial revasculariza-
tion (38%), pulmonary vein ablation (23.8%), left atrial
auriculum resection (52.4%) and PFO/ASD-closure
(11.9%). All but a few important differences between pa-
tients in both arms of our analysis attained statistical sig-
nificance. Patients in the MitraClip cohort had higher
STS risk score (p = 0.008). They were though older, but
the differences did not attain statistical difference (p =
0.100). MitraClip patients also had lower proportion of
individuals in NYHA classes II (p = 0.039), had higher
number of individuals with previous cardiac decompen-
sation (p = 0.006). Patients in the conventional surgical
cohort had higher mean logistic EUROSCORE II, but
the differences did not attain statistical significance (p =
0.655). With regards to echocardiographic parameters,
patients in the MitraClip cohort had higher proportion
of individuals with functional MR, however this differ-
ence did not attain a statistical significance (p = 0.511).
Table 2 shows further echocardiographic parameters.
Procedural and in-hospital outcomes
Procedural success was 100% in the conventional
surgery group and 95.2% in the MitraClip group (p
=0,494). In one MitraClip patient, MR grade was three
at discharge. Another patient with symptomatic MR and
significant inter atrial shunt was treated with mitral
valve replacement and ASD closure prior to discharge.
Thirty surgical patients (71.4%) received an annuloplasty






MR ≥ 3, n (%) 42 (100) 42 (100)
LVEF, mean ± SD, (n) 53.4 ± 14.3, (38) 47.6 ± 14.2, (42) 0.072῀
LVEDD (mm), mean ± SD, (n) 55.3 ± 7.47, (30) 57.5 ± 9.54, (42) 0.296῀
LVESD (mm), mean ± SD, (n) 38.2 ± 6.81, (12) 44.1 ± 10.6, (42) 0.077῀
sPAP (mmHg), mean ± SD, (n) 47.2 ± 8.04, (13) 51.0 ± 12.2, (42) 0.212῀
MR Type
Functional, n (%) 17 (40.5) 21 (50.0) 0.511*
Organic +mixed, n (%) 25 (59.5) 21 (50.0)
῀ Student’s unpaired t-test
* Fisher’s exact Test for categorical data
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using a complete rigid or semi rigid ring. Twelve
patients received tissue valve replacement (28.6%). Nine
patients in the MitraClip cohort were treated with one
clip device, 22 patients with two clips, eight patients
with three clips and the remaining three patients with
four clips devices each. In-hospital- stay was significantly
increased in the surgical group compared to the
MitraClip group (18.0 ± 7.60 vs 8.81 ± 6.40, p < 0.001)
as well as incidents of acute kidney injury (10 vs 2, p
= 0.026) and pneumonia (12 vs 3, p = 0.020). Details
of periprocedural characteristics of all patients are
depicted in Table 3.
Follow- up, mortality and morbidity
Follow-up was performed at various intervals post index
procedure in both surgical and the MitraClip cohort.
Mean follow-up times were 2.08 ± 1.68 years for the surgi-
cal cohort and 0.75 ± 0.50 years for the MitraClip cohort
respectively for a total of 87.53 and 31.57 patient years
respectively. Overall early mortality and morbidity rates
are shown in Table 3. Three patients (7.1%) in the mitral
surgical cohort died within 30 days of the index proced-
ure. At 1 year this number increased to four (9.5%). In the
MitraClip cohort, two patients (4.8) died within 30 days of
the index procedure and this number increased to nine
(21.42%) at 1 year. Univariate analysis revealed that the
only predictor of 30-day mortality was COPD in both the
MitraClip and surgical cohort (HR 7.26, 95% CI 0.76–
69.9, p = 0.086). None of the other preoperative variables
was significantly associated with this outcome variable
(Table 4). Ventilation time > 24 h was more frequent in
the surgical group. ICU and in-hospital stays (18.0 ± 7.60
vs 8.81 ± 6.40, p < 0.001) were longer in the surgical
cohort. In-hospital-death (3 vs 1, p = 0.616), acute kidney
injury (10 vs 2, p = 0.026), need for dialysis (4 vs 1, p =
0.202), pneumonia (12 vs 3, p = 0.02) and need for per-
manent pacemaker implantation (9 vs 0) were more
frequent in the surgical group (Table 3).
Echocardiographic outcomes
Predischarge MR 0, I° and II° were found in 34, seven
and zero patients versus six, 26 and nine patients in the
mitral surgical and MitraClip groups respectively (p <
001, Table 3). At follow up nine patients in the mitral
surgical group had MR I°, one patient had MR II°. In the
Mitraclip cohort, three patients remained at MR I°, 23
patients had MR I°, nine patients had MR II°, three pa-
tients had MR III°. One Patient had mitral stenosis II°
post intervention in the Mitraclip cohort. In the surgical
cohort, no mitral stenosis was recorded. In general, sur-
gery was more effective in reducing the grade of MR
acutely compared to MitraClip.
Discussion
Mitral valve surgery in the elderly oftentimes multi mor-
bid population is a highly debated issue. Although more
elderly patients with MR are increasingly being identified
and referred for surgery, still as much as 50% are often
denied surgery due to perceived higher risk and lower
benefit expectation from surgical correction of MR [2].
This tendency is partly justifiable for secondary MR due
to the fact that results of surgery are unpredictable in
improving patient outcomes. Moreover surgery for sec-
ondary MR has never been compared with guidelines di-
rected medical therapy (GDMT) alone for left
ventricular dysfunction in a prospective randomized
manner. Studies comparing outcomes of patients with
secondary MR treated with mitral valve repair and those
treated with GDMT are mostly retrospective in nature,
using propensity score matching and have failed to dem-
onstrate an advantage of surgery in improving survival
[13]. However, results of surgical elimination of MR in
primary (degenerative) MR on the other hand, especially
reconstructive surgery are excellent.







mean ± SD, (n)
214.1 ± 57.2, (42) 186.4 ± 73.7, (41) 0.059~
Ventilation time≥ 24h,
n (%)
8 (19.0) 1 (2.4) 0.029*
ICU stay(days), mean ±
SD, (n)
3.71 ± 4.00, (41) (0)
In Hospital stay(days),
mean ± SD, (n)
18.0 ± 7.60, (41) 8.81 ± 6.40, (42) <0.001~
Procedural success, n (%) 42 (100) 40 (95.2) 0.494*
In-hospital-death, n (%) 3 (7.1) 1 (2.4) 0.616*
30-day-mortality, n (%) 3 (7.1) 2 (4.8) 1.000*
Major bleeding, n (%) 2 (4.8) 3 (7.1) 1.000*
Tracheotomy, n (%) 1 (2.4) 0 (0.0)
Acute kidney injury, n (%) 10 (23.8) 2 (4.8) 0.026*
Dialysis post surgery, n (%) 4 (9.8) 1 (2.4) 0.202*
Pneumonia, n (%) 12 (28.6) 3 (7.1) 0.020*
Myocardial infarction, n (%) 1 (2.4) 0 (0.0)
Permanent Pacemaker,
n (%)
9 (21.4) 0 (0.0)
Stroke, n (%) 4 (9.5) 0 (0.0) 0.116*
Predischarge MR Grades,
n (%)
MR 0 34 (82.9) 6 (14.3) <0.001**
MR I 7 (17.1) 26 (61.9)
MR II 0 (0.0) 9 (21.4)
MR III 0 (0.0) 1 (2.4)
~ Student’s unpaired t-test
* Fisher’s exact Test for categorical data
** Chi-square test for categorical data
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Some studies provided insight into potential poorer
prognosis for patients with functional MR and left
ventricular dysfunction and this is especially true for
patients with recent acute myocardial infarction and for
patients with chronic ischemic and non ischemic cardio-
myopathy [14]. It was shown that even with the current
GDMT, there was always a tendency to adverse progno-
sis due to untreated ischemic functional MR. Therefore
this category of patients who remain symptomatic
despite GDMT and CRT may be a reasonable target for
surgical or interventional therapy of functional MR.
Swaans et al. recently reported mortality rates in patients
receiving neither surgery nor percutaneous therapy for
MR that even exceeded that of either surgical or inter-
ventional therapy [15]. This report provided new insights
into the potential survival benefits of mitral valve inter-
vention (both surgical and interventional) compared
with GDMT alone in patients with LV dysfunction and
secondary MR [15]. In the Survival and Ventricular
Enlargement Trial (SAVE) patients with even mild func-
tional MR after myocardial infarction were more likely
to experience cardiovascular mortality (29% vs. 12%; p <
0.001), and severe heart failure (24% vs. 16%; p < 0.0153)
than those without MR [16]. Trichon et al. reported
2057 patients with ischemic MR and chronic LV systolic
dysfunction and showed residual MR to be an independ-
ent predictor of mortality. They also found significantly
lower survival rates at 1, 3 and 5 years of heart failure
patients with moderate to severe MR versus those with-
out MR or with mild MR [17]. Hence, none referral of
elderly symptomatic patients with MR for at least surgi-
cal evaluation, due to age alone is highly debatable. The
optimal timing for surgery or percutaneous intervention
is also critical in reducing mortality rates associated with
Table 4 Predictors of 30- day Mortality in octogenarians treated with MVS vs. MC
univariate Cox Regression
all Patients (n = 84) MVS (n = 42) MC (n = 42)
Variable Hazard Ratio 95%-CI p-value Hazard Ratio 95%-CI p-value Hazard Ratio 95%-CI p-value
Logistic Euroscore
> 10 vs. <=10a ** ** ** ** ** ** ** ** **
NYHA baseline
class 3/4 vs. class 1/2a ** ** ** ** ** ** ** ** **
Baseline LVEF
> 50% vs. <=50%a 1.07 0.07–17.1 0.963 ** ** ** 1.18 0.07–18.9 0.905
Cardiac decompensation
yes vs. noa ** ** ** ** ** ** ** ** **
Age
80–82 years vs. 83–85 yearsa ** ** ** ** ** ** ** ** **
Sex
female vs. malea 1.11 0.16–7.85 0.920 ** ** ** ** ** **
Coronary artery disease
yes vs. noa 1.44 0.15–13.8 0.753 ** ** ** 0.60 0.04–9.53 0.714
Diabetes mellitus
no vs. yesa 1.82 0.19–17.5 0.604 ** ** ** 0.77 0.05–12.3 0.851
COPD
yes vs. noa 7.26 0.76–69.9 0.086 2.85 0.18–45.6 0.459 ** ** **
GFR≤ 30
yes vs. noa ** ** ** ** ** ** ** ** **
GFR 30–50
yes vs. noa 1.77 0.25–12.5 0.570 ** ** ** ** ** **
Atrial fibrillation
yes vs. noa 1.68 0.17–16.1 0.655 0.71 0.04–11.4 0.810 ** ** **
Pulmonary hypertension
yes vs. noa ** ** ** ** ** ** ** ** **
**not determinable, because there are only censored times
aindicates reference category
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both surgery and interventional therapy. The percutaneous
edge-to-edge device has since its first application in human,
continuously improved, and currently demonstrates superb
acute interventional outcomes in the elderly population
with MR classified as high surgical risk [18, 19]. Though op-
erative risks of mitral valve surgery reduced significantly
during the last decades [20], however quality of life after
such surgical interventions, a factor of great importance in
the elderly population has rarely been reported. Maissano et
al [21] found that quality of life was suboptimal in more
than half of elderly patients following mitral valve surgery
and that surgical technique did not impact quality of life at
follow up. They identified several factors significantly related
to increased Minnesota Living With Heart Failure (MLHF)
- score at follow-up after valve surgery in the elderly. Age,
preoperative atrial fibrillation (or rhythm other than sinus
rhythm at follow up), EuroSCORE, Charlson score and re-
current/residual MR at follow up amongst others were sig-
nificantly associated with poorer quality of life at follow up.
They suggested that quality of life should be a better indica-
tor of successful surgery/intervention in this age group than
survival alone. In our study, though the 30-day mortality
was slightly higher in the surgical cohort, but there was
equalization of mortality rates as time progressed, with even
higher mortality rate in the MitraClip group (depicted in
Fig. 1). At 1- year- follow up surgical patients had lower MR
recurrence than found in the Mitraclip group. Kaneko
et al in their recent study found that residual MR 2+
was associated with poorer prognosis in patients with
impaired LV function, renal dysfunction, and severe
heart failure. They suggested that the optimal end-
point of MC procedure should be individualized ac-
cording to each patient's baseline characteristic [22].
The impact of tricuspid regurgitation left untreated at
time of Mitraclip intervention was recently reported by
ohno et al [23] who found that estimates for freedom
from combined endpoint of death and rehospitalisation
for heart failure were worse in moderate/severe tricuspid
regurgitation group of patients treated with the Mitra-
Clip device compared with those with none/mild tricus-
pid regurgitation (67.7% vs 88.8% log-rank p = 0.015).
Overall NYHA was also found to be worse in this group
of patients with moderate/severe tricuspid regurgitation,
despite improved LVEF and ventricular volumes at
12 month-follow-up. Since the current practice of Mitra-
clip intervention does not include concomitant cardiac
interventions in the aortic valve, tricuspid valve, atrial
fibrillation ablation or complete myocardial revasculari-
sation, all of which have high prevalence in the elderly
population, adequate patient selection should identify
patients who would rather benefit from complete surgi-
cal intervention despite age.
Mitral valve surgical procedures in the very elderly
with symptomatic MR is associated with profound op-
erative morbidity and mortality rates, especially in deem
of frequently associated comorbidities [10]. Mirabel et al
[2] from the Euro Heart Survey on heart valve diseases
reported that in a group of 396 patients with symptom-
atic MR, surgery was denied in 49%, with age, impaired
LVEF and several comorbidities playing the main role in
the decision not to offer surgery. However untreated
symptomatic secondary MR seems to confer even higher
mortality and morbidity. MitraClip therapy, though has
acceptable procedural outcomes, but long term results
are pending and the durability of acute reduction of MR
in certain patients remains controversial. De Bonis et al.
Fig. 1 Kaplan-Meier survival rate after MitraClip and surgery
Alozie et al. BMC Cardiovascular Disorders  (2017) 17:85 Page 7 of 9
recently failed to confirm the results of EVEREST II trial
in which it was observed that the MItraClip results
remained stable in the long term if initial therapy was
successfull. Infact they found that patients with FMR,
despite optimal initial results of MitraClip intervention
had the tendency to develop recurrent MR. Whether
FMR at this time can be seen as risk factor for recurrent
MR after MitraClip therapy remain to be confirmed in a
prospective randomized trial.
Treatment of concomitant cardiac pathologies, which
have increased prevalence in this age group, is very lim-
ited. The impact of untreated concomitant cardiac path-
ologies, left untreated at the time of MitraClip therapy
versus complete surgical interventions on the mid and
long term outcomes should be the subject of future
studies. Our acute procedural outcomes in the mitral
surgical group is in line with published data on mortality
and morbidity rates after mitral valve surgery in the very
elderly, despite several concomitant surgical procedures
and high EuroScore II values, and mid term outcomes
are impressive.
As the number of elderly patients with mitral valve
disease is expected to increase rapidly, there is need for
data providing evidence on the benefits and harm of
both conventional MV surgery and several percutaneous
therapeutic options, being propagated for MR treatment
in these high risk patients. As percutaneous mitral
valve repair options are rapidly gaining ground as al-
ternative option for mitral valve repair in these high
risk surgical patients, at the same time some patients
are reoperated successfully after failed interventions.
However this is expected to decrease with perfection
of this technology. Adequate patient selection prior to
decision for either conventional surgery or MitraClip
therapy should be pursued in the future. Age alone
should at present not be a criterium for pro Mitra-
Clip therapy, rather comorbidities predisposing to
high prohibitive risk of surgery and in those cases
with ambiguous survival benefit of surgery. Benefit of
surgery for MR due to ischemic cardiomyopathy re-
mains a highly debated issue [24–26]. Multidisciplin-
ary team approach is key to providing optimal
individually tailored treatment for elderly patients
with symptomatic MR. Primary and secondary MR
are very different entities in terms of etiology, man-
agement and prognosis and these differences should
be put into account during multidisciplinary decision
pro or contra surgery or interventional treatment of
symptomatic MR.
Study limitations
This is a retrospective, single-center observational study
with a very limited number of observed patients. There
may be some, unidentified confounding factors that
might have influenced certain results, so strong conclu-
sions from our study should not yet be deduced or gen-
eralized, until our results is confirmed by prospective
and randomized clinical trials. Follow-up data were
obtained by both facsimile questionnaire and telephone
interviews with patients family practitioner and cardiolo-
gist. Hence, accuracy of grading NYHA functional class,
MR grades may have been compromised by interob-
server bias. Patient selection for the respective proce-
dures did not follow standard operating procedures, but
rather decisions were made after interdisciplinary
consultation in each case within a heart team. The
completely different burden of both treatment arms,
with patients in the surgical arm receiving different and
at times multiple concomitant procedures with subse-
quent impact on early clinical outcome is another im-
portant limitation.
In terms of quality of life, unfortunately due to the
retrospective nature of our study, quality of life was not
assessed preoperatively and therefore assessing quality of
life during follow-up would not provide data usefull for
any reasonable comparison.
Another important limitation is that the number of
patients whose data were available for 1-year followed-
up was less in the mitraClip group.
Conclusions
Elderly patients presenting with moderate to severe
symptomatic MR may either be treated by conventional
surgery or with the MitraClip device with acceptable
acute outcomes. The decision for treatment with the
MitraClip device should not depend on age alone rather
on cumulative risk of conventional surgery. Concomitant
cardiac pathologies, often times treated simultaneously
during surgery for symptomatic MR may be omitted, if
patients are scheduled outright to MitraClip treatment.
The effect of concomitant cardiac pathologies left untreated
at the time of interventional mitral valve repair on outcome
after MitraClip therapy remain widely unknown.
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